ReviewFrontiers in immunology2017
CD4 CTL, a Cytotoxic Subset of CD4
Review in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 277 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
277 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pooled it
- Exploring Localized Provoked Vulvodynia: Insights from Animal Model Research.International journal of molecular sciences · 2024Pooled it
- T-cell receptor variable region usage in Chagas disease: A systematic review of experimental and human studies.PLoS neglected tropical diseases · 2022Pooled it
- The dichotomous and incomplete adaptive immunity in COVID-19 patients with different disease severity.Signal transduction and targeted therapy · 2021Trial
- Targeting BCL9/BCL9L enhances CD4Acta pharmacologica Sinica · 2026Article
- Cytotoxic CD4Nature aging · 2026Article
- Peripheral CD4 T-Cell State Remodeling in Migraine Revealed by Single-Cell RNA Sequencing.Journal of molecular neuroscience : MN · 2026Article
- Cytotoxic CD4Parasite immunology · 2026Article
- Integrated immune profiling identifies a coordinated T-cell activation and inflammatory signature in SLE.Lupus science & medicine · 2026Article
- L-type voltage-gated CaEMBO reports · 2026Article
- Immune-Related Gene Variants as Modifiers of Multiple Sclerosis Severity.International journal of molecular sciences · 2026Article
- Identifying Negative Biomarkers of CD4 Cytotoxic T Lymphocytes via Granzyme B Exclusion Analysis.European journal of immunology · 2026Article
- Whole-protein screening and multi-modal profiling of antigen-specific CD4Nature communications · 2026Article
- DNA origami vaccine nanoparticles improve humoral and cellular immune responses to infectious diseases.Nature biomedical engineering · 2026Article
- Cytotoxic CD4Signal transduction and targeted therapy · 2026Review
- Cytotoxic CD4 T Cells: Dual Agents in HIV-1 Pathogenesis and Persistence.Current HIV/AIDS reports · 2026Review
- DNA methylation-mediated silencing of MEOX1 promotes glycolysis and immune evasion in colorectal cancer cells through inhibition of GLP2R transcription.Cell & bioscience · 2026Article
- CD4+ T Cells Mediate MHC-Deficient Tumor Rejection and Endothelial Cell Reprogramming.Cancer immunology research · 2026Article
- FCRL3 is an immunoregulatory receptor that restrains the activation of human memory T lymphocytes.The Journal of experimental medicine · 2026Article
- Checkpoint inhibition and beyond: Precision immune engineering for the immune-privileged landscape of ocular malignancies.BioImpacts : BI · 2026Review
217 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.